Copenhagen Stock Exchange:NOVO B - United States News Beep

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Read More

Novo Nordisk and Omeros announce asset purchase and license

October 15, 2025

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…